Showing results (11-20 of 140) with videos related to
Sort By:
Pageof 14
Leukemia & Lymphoma|December 30, 2009
A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemiaRichard R Furman, Andres Forero-Torres, Andrei Shustov, et al.Clinical Advances in Hematology & Oncology : H&O|May 30, 2014
Clinical roundtable monograph: unmet needs in the treatment of chronic lymphocytic leukemia: integrating a targeted approachSusan M O'Brien, Richard R Furman, John C Byrd, et al.AIDS Patient Care and Stds|February 23, 2008
Improving outcomes for patients with Burkitt lymphoma and HIVVictoria S Blinder, Amy Chadburn, Richard R Furman, et al.Journal of Hematopathology|March 5, 2011
NK/T cell non-Hodgkin lymphoma in a HIV-positive patientNicole C Panarelli, Richard R Furman, Y Lynn Wang, et al.The Oncologist|August 7, 2014
Extracorporeal membrane oxygenation as a bridge to chemotherapy in an Orthodox Jewish patientEllen C Meltzer, Natalia S Ivascu, Cathleen A Acres, et al.Clinical Lymphoma, Myeloma & Leukemia|December 31, 2013
Long-term follow-up of R-CHOP with bevacizumab as initial therapy for mantle cell lymphoma: clinical and correlative resultsJia Ruan, Stephanie A Gregory, Paul Christos, et al.Seminars in Hematology|April 3, 2008
Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphomaPeter Martin, Richard R Furman, Jia Ruan, et al.Journal of the American Academy of Dermatology|June 15, 2010
Cutaneous CD4+ CD56+ hematologic malignanciesCynthia M Magro, Pierluigi Porcu, Jochen Schaefer, et al.Frontiers in Oncology|December 3, 2021
Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical PracticeSusan M O'Brien, Jennifer R Brown, John C Byrd, et al.Blood|January 27, 2010
Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathwaysRhona Stein, Pankaj Gupta, Xiaochuan Chen, et al.Pageof 14